AmyriAD Therapeutics Acquires Recognify Life Sciences to Expand Cognition Pipeline
AmyriAD Therapeutics has acquired Recognify Life Sciences and its lead clinical-stage compound RL-007 (inidascamine), expanding AmyriAD's focus on cognition in central nervous system disorders. The all-share transaction brings shareholders of Recognify, including atai Life Sciences, Catalio Capital Management, and Sudhoff Family Office, into ownership of AmyriAD. RL-007 is a first-in-class pro-cognitive compound with potential applications for cognitive impairment associated with schizophrenia (CIAS) and Alzheimer's disease. RL-007 has been tested in 500 subjects to date and demonstrated consistent safety without sedation, weight gain, or extrapyramidal symptoms. AmyriAD plans to optimize the formulation of RL-007 through an ongoing pharmacokinetic study with results expected by early 2027. The company will also advance development for CIAS, where cognitive impairment affects over 80% of schizophrenia patients globally and remains underserved. AmyriAD intends to leverage its existing infrastructure from the ismidenon program in Alzheimer's disease to support RL-007’s clinical trials. Ranga Krishnan, Chair of AmyriAD, emphasized that this acquisition aligns with the company's mission by adding a differentiated mechanism and expanding into another key CNS indication.
